Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19043264 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | January 2025 | November 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 19043275 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | January 2025 | December 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 19043303 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | January 2025 | December 2025 | Allow | 11 | 1 | 0 | No | No |
| 19030516 | AMINO ACID COMPOSITIONS | January 2025 | January 2026 | Allow | 12 | 3 | 0 | No | No |
| 19030637 | AMINO ACID COMPOSITIONS | January 2025 | September 2025 | Allow | 8 | 1 | 1 | No | No |
| 19030390 | AMINO ACID COMPOSITIONS | January 2025 | January 2026 | Allow | 12 | 1 | 1 | Yes | No |
| 19030189 | AMINO ACID COMPOSITIONS | January 2025 | December 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18947694 | Liquid Tasimelteon Formulations and Methods of Use Thereof | November 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18932033 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | October 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18745858 | AMINO ACID COMPOSITIONS | June 2024 | June 2025 | Allow | 12 | 2 | 1 | No | No |
| 18665714 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18626876 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | April 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18604704 | ISATIN DERIVATIVES | March 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18601088 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | March 2024 | March 2026 | Allow | 24 | 2 | 0 | No | No |
| 18582125 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | February 2024 | November 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18443889 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18416417 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof | January 2024 | September 2025 | Allow | 20 | 1 | 0 | No | No |
| 18415561 | COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF | January 2024 | September 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18409959 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | January 2024 | July 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18577088 | A System and Method for Measuring and Stimulating Autophagy | January 2024 | June 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18403049 | O-{1-[(3,5-DINITROBENZOYL)AMINO]PROPAN-2-YL} (4-CHLOROPHENYL)CARBAMOTHIOATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | January 2024 | April 2024 | Allow | 3 | 1 | 0 | No | No |
| 18391243 | DRUG DELIVERY FORMULATIONS | December 2023 | September 2024 | Allow | 9 | 2 | 0 | No | No |
| 18571819 | HERBICIDAL ARYLDIHYDROFURANE CARBOXYLATES | December 2023 | March 2026 | Allow | 26 | 0 | 0 | No | No |
| 18537093 | METHODS OF TREATING OR CONTROLLING CYTOTOXIC CEREBRAL EDEMA | December 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18534234 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | December 2023 | January 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18530282 | ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS | December 2023 | November 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18387170 | COMBINATION THERAPIES | November 2023 | December 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18165413 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | October 2023 | November 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 18379753 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18478249 | Growth Differentiation Factor 15 as Biomarker for Metformin | September 2023 | July 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18552908 | USE OF CHOLECALCIFEROL AS ADJUVANT IN THE TREATMENT OF MUSCULAR DYSTROPHIES | September 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18475736 | NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS | September 2023 | September 2025 | Allow | 23 | 2 | 0 | No | No |
| 18471748 | BIOADHESIVE FOR CORNEAL REPAIR | September 2023 | January 2026 | Allow | 28 | 1 | 1 | No | No |
| 18368497 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | September 2023 | May 2025 | Allow | 20 | 2 | 0 | No | No |
| 18367103 | METHODS FOR TREATING CANCER | September 2023 | September 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18241881 | SYNERGISTIC COMBINATIONS OF ATORVASTATIN AND CANNABIDIOL (CBD) | September 2023 | June 2024 | Allow | 9 | 1 | 0 | No | No |
| 18456178 | TELOMERASE ACTIVATING COMPOUNDS FOR USE IN FERTILITY AND RELATED APPLICATIONS | August 2023 | November 2025 | Allow | 27 | 2 | 1 | No | No |
| 18450564 | METHOD OF TREATMENT WITH TRADIPITANT | August 2023 | March 2026 | Abandon | 31 | 2 | 0 | No | No |
| 18446059 | BROMHEXINE FOR THE TREATMENT OF PAIN | August 2023 | November 2025 | Allow | 27 | 1 | 1 | No | No |
| 18365266 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18362194 | Liquid Tasimelteon Formulations and Methods of Use Thereof | July 2023 | August 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18227094 | CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF | July 2023 | December 2025 | Allow | 29 | 1 | 0 | No | No |
| 18227168 | PRODUCTS AND METHODS FOR MICROBE INHIBITION ON LIVE PLANTS BY CARBOXYLIC ACIDS AND THEIR SALTS | July 2023 | April 2025 | Allow | 21 | 1 | 0 | No | No |
| 18357945 | COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION | July 2023 | February 2026 | Abandon | 31 | 1 | 1 | No | No |
| 18224898 | Compositions and Methods for Treating Defects in Avascular Cartilaginous Tissue by Directly Administering One or More Metabolites of Simvastatin | July 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18342387 | METHODS FOR TREATING HEART FAILURE BY ADMINISTERING CARDIAC SARCOMERE ACTIVATORS | June 2023 | January 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18334738 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | June 2023 | December 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18333532 | Compounds and Methods for Treating or Preventing Anterior Segment Ocular Disorders and/or Retinal Degenerations | June 2023 | April 2025 | Allow | 22 | 2 | 0 | No | No |
| 18199812 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18316841 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18316730 | FOLATE SALTS FOR MEDICAL USE | May 2023 | January 2026 | Allow | 33 | 2 | 0 | No | No |
| 18195245 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF ALCOHOL DEPENDENCE USING IBOGAINE AND DERIVATIVES THEREOF | May 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18308723 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | April 2023 | January 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18250560 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | April 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18032944 | Crystalline Solid Meglumine Salt Inhibitor of BCL and Methods of Making and Using Same | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18298175 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | April 2023 | November 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18130059 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | April 2023 | September 2024 | Allow | 17 | 1 | 0 | No | No |
| 18187385 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18113458 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2023 | November 2023 | Allow | 9 | 2 | 1 | Yes | No |
| 18042170 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IDIOPATHIC PULMONARY FIBROSIS | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18042252 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | February 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18170301 | METHOD OF TREATMENT OF SCHIZOPHRENIA | February 2023 | October 2025 | Allow | 32 | 2 | 1 | No | No |
| 18041728 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | February 2023 | January 2026 | Allow | 37 | 1 | 1 | No | No |
| 18107886 | METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | February 2023 | October 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18040862 | NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF | February 2023 | September 2025 | Allow | 32 | 0 | 1 | No | No |
| 18165908 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | February 2023 | February 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18100426 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | January 2023 | April 2025 | Allow | 27 | 1 | 1 | No | No |
| 18100039 | INTRATHECAL ADMINISTRATION OF LEVETIRACETAM | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18014738 | COMPOSITIONS COMPRISING THYMOL AND AMINO ACIDS FOR USE IN THE TREATMENT OF INFLAMMATORY OR FUNCTIONAL INTESTINAL DISORDERS | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18148659 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | December 2022 | August 2023 | Allow | 8 | 2 | 0 | No | No |
| 18089920 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | December 2022 | January 2025 | Allow | 25 | 2 | 1 | No | No |
| 18082810 | COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR | December 2022 | July 2025 | Allow | 31 | 1 | 0 | No | No |
| 18071344 | Treatment of Autism Spectrum Disorders with Ergothioneine, Selenoneine, or Combinations Thereof | November 2022 | April 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18058064 | COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES | November 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 17989174 | CARBAMOYL CYCLOHEXANE DERIVATIVES FOR TREATING AUTISM SPECTRUM DISORDER | November 2022 | March 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17986934 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17981220 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | November 2022 | June 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17968232 | COMPOUNDS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH EXTRA-INTESTINAL MANIFESTATIONS | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 18046876 | NOVEL TREATMENT FOR HOT FLUSHES | October 2022 | November 2024 | Allow | 25 | 2 | 0 | No | No |
| 17960343 | Ephedrine Compositions and Methods | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17954421 | PHARMACEUTICAL FORMULATION OF PALBOCICLIB AND A PREPARATION METHOD THEREOF | September 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17947509 | NEURONAL MODULATION | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17946585 | Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17943986 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | September 2022 | February 2025 | Allow | 29 | 2 | 1 | No | No |
| 17942486 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY | September 2022 | March 2025 | Allow | 30 | 2 | 1 | No | No |
| 17930824 | Varenicline Compound and Process of Manufacture Thereof | September 2022 | June 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17930940 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | September 2022 | August 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17941627 | SLEEP IMPROVING AGENT | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17930538 | THIENOPYRROLE COMPOUNDS | September 2022 | April 2024 | Allow | 19 | 1 | 1 | No | No |
| 17930570 | ANHYDROUS COMPOSITIONS OF EGFR INHIBITORS AND METHODS OF USE | September 2022 | June 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17823546 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | August 2022 | May 2023 | Allow | 8 | 1 | 1 | No | No |
| 17897944 | FORMULATIONS FOR DELIVERY TO THE EAR | August 2022 | May 2025 | Abandon | 33 | 2 | 1 | Yes | No |
| 17821869 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | February 2023 | Allow | 6 | 2 | 1 | Yes | No |
| 17893905 | TREATMENT OF CNS CONDITIONS | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17821157 | METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS | August 2022 | August 2025 | Allow | 36 | 4 | 0 | No | No |
| 17891662 | RESVERATROL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | August 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17821146 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | August 2022 | March 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 17877339 | CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF | July 2022 | August 2024 | Allow | 25 | 2 | 1 | No | No |
| 17873453 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRONCHOPULMONARY DYSPLASIA (BPD) AND BPD-ASSOCIATED PULMONARY HYPERTENSION | July 2022 | April 2025 | Allow | 33 | 4 | 1 | No | No |
| 17813760 | EYE WASH COMPOSITIONS AND METHODS | July 2022 | February 2024 | Allow | 19 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PIHONAK, SARAH.
With a 11.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PIHONAK, SARAH works in Art Unit 1627 and has examined 1,534 patent applications in our dataset. With an allowance rate of 57.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner PIHONAK, SARAH's allowance rate of 57.1% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PIHONAK, SARAH receive 1.84 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PIHONAK, SARAH is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +52.4% benefit to allowance rate for applications examined by PIHONAK, SARAH. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 54.4% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 42.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 39% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 76.1% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 70.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 55.5% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.